Pharmacy Learning NetworkGlobal GLP-1 Agonist Market Trends

Expanding Horizons in Diabetes Management: The Rising Tide of GLP-1 Agonist Market Growth and Cardiovascular Benefits

The global market for GLP-1 (glucagon-like peptide 1) agonists is witnessing a significant upsurge, fueled by their increasing adoption in managing type 2 diabetes mellitus (T2DM) and associated cardiovascular risks. This comprehensive analysis looks into the market dynamics, revealing trends, growth drivers, and potential challenges, providing physicians with a succinct overview to inform their clinical practices.

Key Points:

• The GLP-1 agonist market experienced a robust growth rate of 20.6% CAGR from 2020 to 2023, with projections indicating a rise to $133.5 billion by 2030.
• In 2022, the market valuation stood at $18.75 billion, underscored by global economic contributions and forecasts encompassing regions like the United States, Canada, and several European countries.
• An increase in type 2 diabetes mellitus prevalence, particularly in emerging economies, is catalyzing the demand for GLP-1 agonists, underscoring the need for effective diabetes management strategies.
• GLP-1 agonists, available in short-acting and long-acting formulations, are favored for their efficacy in glycemic control, reducing plasma glucose levels, and aiding in weight loss.
• Besides glycemic control, GLP-1 agonists show promise in mitigating major adverse cardiovascular events, making them a recommended option for T2DM patients with a history of cardiovascular diseases.
• Innovations in GLP-1 agonist delivery methods, including oral and once-weekly injections, are enhancing patient compliance and satisfaction, potentially boosting market growth.
• The ongoing research and development in the GLP-1 agonist sector are poised to introduce more effective treatment alternatives, promising better outcomes for patients and further market expansion.

The number of patients with diabetes mellitus (DM) continues to increase worldwide, and DM is the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The total number of new patients who started renal replacement therapy (RRT) for ESRD increased from 10,000 in 2011 to 18,642 in 2019. Despite advances in medical technology and treatments, the need for RRT is increasing worldwide and is expected to more than double by 2030 compared with 2010.

More on GLP-1 Agonists